Generics Firms On Standby With Tecfidera Appeal Due ‘At Any Time’
Implication Of Potential Pro-Biogen Ruling Unclear
Biogen feels a decision on its appeal over Tecfidera is due any day now, but management was cautious over the potential to scrub the market of generics following market formation last year.
You may also be interested in...
Federal Circuit Cements Viatris Victory Over Biogen On Key US Tecfidera Patent
As anticipated by the street, Viatris has prevailed over Biogen on the originator’s appeal of a district court ruling that invalidated a key US patent shielding its Tecfidera treatment for multiple sclerosis. However, the Federal Circuit was not aligned on its decision.
What’s Next? Five Things To Look Out For In November
In November, ANI Pharmaceuticals is hoping to complete a major acquisition, Viatris may shed further light on the state of the US generics industry and Generics Bulletin will host its eighth annual Global Generics & Biosimilars Awards, this year once again in person.
A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen
Biogen has been granted new US patents for Tecfidera after generics already launched. It's unclear how Biogen will proceed but management could shed more light on the matter during the first quarter call.